Sobell, J. M., Elewski, B., Banerjee, S., Balagula, E., Scharnitz, T., Berger, V., Hoyt, K., Yamauchi, P., Bettencourt, M., Cameron, M. C., & Lebwohl, M. (2023). Deucravacitinib, an Oral, Selective, Allosteric Tyrosine Kinase 2 Inhibitor, in Moderate to Severe Plaque Psoriasis: Efficacy by Baseline Body Surface Area (BSA) Involvement and Baseline Psoriasis Area and Severity Index (PASI). SKIN The Journal of Cutaneous Medicine, 7(6), s238.